Related references
Note: Only part of the references are listed.Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design
Christopher R. Butler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans
Patrick C. May et al.
JOURNAL OF NEUROSCIENCE (2015)
Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter beta-amyloid levels in the CNS
Biljana Georgievska et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β
Simon J. Henderson et al.
BRAIN (2014)
Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein
Janice A. Maloney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
CNS Amyloid-β, Soluble APP-α and -β Kinetics during BACE Inhibition
Justyna A. Dobrowolska et al.
JOURNAL OF NEUROSCIENCE (2014)
Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig
Juliette Janson et al.
PHARMACEUTICAL RESEARCH (2014)
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
Robert Vassar
ALZHEIMERS RESEARCH & THERAPY (2014)
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
Kelly Willemijn Menting et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839
Erik Sparve et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
The Structural Evolution of beta-Secretase Inhibitors: A Focus on the Development of Small-Molecule Inhibitors
Stefania Butini et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Susanna Eketjall et al.
JOURNAL OF NEUROSCIENCE (2013)
Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease
Fredrik Jeppsson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain
Ylva Gravenfors et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer's Disease
Hongbing Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides
Britt-Marie Swahn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy
Tomas Borgegard et al.
JOURNAL OF NEUROSCIENCE (2012)
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline
Thorlakur Jonsson et al.
NATURE (2012)
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
Patrick C. May et al.
JOURNAL OF NEUROSCIENCE (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Species Independence in Brain Tissue Binding Using Brain Homogenates
Li Di et al.
DRUG METABOLISM AND DISPOSITION (2011)
Development of a High-Throughput Brain Slice Method for Studying Drug Distribution in the Central Nervous System
Markus Friden et al.
DRUG METABOLISM AND DISPOSITION (2009)
Application of a Dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates
Yun W. Alelyunas et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
First Demonstration of Cerebrospinal Fluid and Plasma A beta Lowering with Oral Administration of a beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates
Sethu Sankaranarayanan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Extensions to the Visual Predictive Check to facilitate model performance evaluation
Teun M. Post et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice
Lisa McConlogue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Macrocyclic inhibitors of β-secretase:: Functional activity in an animal model
Shawn J. Stachel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
γ-Secretase complexes containing N- and C-terminal fragments of different presenilin origin retain normal γ-secretase activity
K Strömberg et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations
E Floby et al.
XENOBIOTICA (2004)
Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis (Withdrawn Publication. See vol. 298, 2022) (Withdrawn Publication. See vol. 298, 2022)
L Puglielli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Share Paper
